Nifty below 17,800; Sensex drops 117 pts; Pharma stocks decline

Image
Capital Market
Last Updated : Sep 21 2022 | 2:50 PM IST
The key equity indices continued to trade with minor losses in the mid-afternoon trade. The Nifty traded below the 17,800 mark. FMCG and media stocks advanced while metal, pharma and private bank shares corrected.

At 14:28 IST, the barometer index, the S&P BSE Sensex, was down 117.15 points or 0.20% to 59,602.59. The Nifty 50 index declined 52.90 points or 0.30% to 17,763.35.

In the broader market, the S&P BSE Mid-Cap index lost 0.34% while the S&P BSE Small-Cap index slipped 0.35%

The market breadth was weak. On the BSE, 1,332 shares rose, and 2,066 shares fell. A total of 151 shares were unchanged.

Investors turned cautious ahead of the Federal Reserve's monetary policy decision. A three-quarter point increase in rate is expected. But investors are turning their attention to the Fed's updated economic projections, which will show what the Fed thinks about the endpoint on rates as well as its forecasts for inflation and employment.

Fed officials have talked in recent weeks about their determination to tame inflation, using whatever it took, despite any pain that may cause to the economy. Such a stance could also mean a recession in the near future.

Numbers to Track:

The yield on India's 10-year benchmark federal paper rose to 7.264 as compared with 7.294 at close in the previous trading session.

In the foreign exchange market, the rupee was lower against the dollar. The partially convertible rupee was hovering at 79.79, compared with its close of 79.74 during the previous trading session.

MCX Gold futures for 5 October 2022 settlement declined 0.49% to Rs 49,417.

The US Dollar index (DXY), which tracks the greenback's value against a basket of currencies, added 0.18% to 110.74.

In the commodities market, Brent crude for November 2022 settlement rose $2.46 or 2.71% at $93.08 a barrel.

Buzzing Index:

The Nifty Pharma index declined 1.03% to 12,619.05. The index rose 3.26% in past two trading sessions.

Gland Pharma (down 3.6%), Biocon (down 2.13%), Laurus Labs (down 1.64%), Alkem Laboratories (down 1.24%), Cipla (down 1.19%), Aurobindo Pharma (down 1.15%), Divis Laboratories (down 1.15%), Dr Reddys Laboratories (down 1.14%), Natco Pharma (down 1.06%) and Torrent Pharmaceuticals (down 0.99%) declined.

On the other hand, Granules India (up 1.98%),Strides Pharma Science (up 0.47%) and Alembic Pharmaceuticals (up 0.32%) edged higher.

Stocks in Spotlight:

Central Bank of India jumped 7.13% after the Reserve Bank of India (RBI) decided to remove the public sector bank from prompt corrective action (PCA) framework. RBI on Tuesday (20 September) said the Board for Financial Supervision reviewed the performance of the Central Bank of India. The regulator noted that as per the assessed figures of the bank for the year ended 31 March, it is not in the breach of the PCA parameters.

Intellect Design Arena rose 0.38% after it said that Cathay United Bank has chosen to implement Intellect Global Consumer Banking's (iGCB) digital credit platform 'iKredit 360' to power the next growth stage of their lending business. One of the largest and most prestigious financial groups in Taiwan, Cathay Financial Holdings has been in Vietnam for over 20 years now.

C.E. Info Systems (MapMyIndia) declined 0.28%. The company announced that it has acquired 26.37% stake in Kogo Tech Labs to build travel & hyper-local discovery, commerce, social, gamified platform integrated with maps and navigation. The cost of acquisition of 26.37% stake stood at $1.25 million (Rs 10 crore) along with an option to raise stake to 50% in two years.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 21 2022 | 2:32 PM IST

Next Story